Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Vi-CRM197 as a new conjugate vaccine against Salmonella Typhi

Micoli, Francesca, Rondini, Simona, Pisoni, Ivan, Proietti, Daniela, Berti, Francesco, Costantino, Paolo, Rappuoli, Rino, Szu, Shousun, Saul, Allan and Martin, Laura (2010) Vi-CRM197 as a new conjugate vaccine against Salmonella Typhi. Vaccine, 29 (4). pp. 712-720. ISSN 0264-410X


An efficacious, low cost vaccine against typhoid fever, especially for young children, would make a major impact on disease burden in developing countries. The virulence capsular polysaccharide of Salmonella Typhi (Vi) coupled to recombinant mutant Pseudomonas aeruginosa exoprotein A (Vi-rEPA) has been shown to be highly efficacious. We investigated the use of carrier proteins included in infant vaccines, standardized the conjugation process and developed key assays required for routine lot release at production scale. Vi from a BSL1 organism, Citrobacter freundii, strain WR7011, was used as an alternative to Vi from S. Typhi. We showed that Vi conjugated to CRM197, a non-toxic mutant of diphtheria toxin, widely used in commercial vaccines, was produced at high yield. Vi-CRM197 proved immunogenic in animal studies, even without adjuvant. Thus, Vi-CRM197 appears to be a suitable candidate for the development of a commercially viable, effective typhoid vaccine for developing countries.

Item Type: Article
Related URLs:
Additional Information: author can archive post-print (ie final draft post-refereeing); Publisher's version/PDF cannot be used
Keywords: Vi; Conjugate vaccine; Salmonella Typhi
Related URLs:
Date Deposited: 13 Oct 2015 13:15
Last Modified: 13 Oct 2015 13:15